[Stock in Focus] Mezoo Soars to Triple Its IPO Price on First Day of KOSDAQ Listing
Mezoo surged to more than three times its initial public offering (IPO) price on its first day of trading on KOSDAQ.
As of 9:12 a.m. on March 26, Mezoo was trading at 66,200 won, up 44,600 won (206.48%) from its IPO price of 21,600 won.
Mezoo is a digital healthcare company founded by biomedical engineering Ph.D. researchers from Yonsei University's Wonju Campus. The company has developed and commercialized a platform that addresses gaps in patient monitoring both inside and outside of hospitals, based on its biosignal measurement and analysis technology. In particular, by leveraging its portable remote patient monitoring technology—which takes into account patient mobility and daily environments—Mezoo has supplemented the limitations of hospital-centered monitoring and has built a platform that can be further expanded into patients' daily lives.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Mezoo plans to accelerate its transition into a global medical data-based platform company by establishing distribution networks focused on North America and Europe, expanding local sales, marketing, and joint research, and advancing its AI-based prediction and diagnosis technology. In addition, the company aims to further expand its presence in the domestic hospital market through collaboration with Dong-A ST, its strategic investor and the domestic distributor of HiCardi.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.